Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | GCKR | Q14397 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL16667596 | 0.89 | CYP11B1 (0.42) | ALDH1A1MEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL12304375 | 0.81 | DHFR (0.38) | ALDH1A1ALOX5APFEN1KDM4EPOLB | |
| SCHEMBL16649161 | 0.79 | CYP11B1 (0.46) | ALDH1A1MEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL2634852 | 0.78 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL4766176 | 0.78 | CYP11B1 (0.42) | ALDH1A1MEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL30055347 | 0.78 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL16139574 | 0.78 | CYP11B1 (0.42) | ALDH1A1MEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL1714544 | 0.76 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL9446803 | 0.76 | GCK (0.38) | ALDH1A1MEN1KMT2AALOX5APFEN1 | |
| SCHEMBL921763 | 0.75 | KHK (0.43) | ALDH1A1MEN1KMT2ACYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160102100-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2016-04-14 | — | — | US | disclosed |
| EP-1755572-B1 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2012-02-15 | — | — | EP | disclosed |
| US-7763659-B2 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7629367-B2 | Tissue-selective androgen receptor modulators (SARMs); male hypogonadism, prostate cancer, benign prostate hyperplasia, sarcopenia, rheumatoid arthritis and osteoarthritis; N-((5-cyclopropyl-2-fluoropyridin-3-yl)methyl)-2-phenylbutanamide for example | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080139630-A1 | N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-06-12 | — | — | US | disclosed |
| US-20070225229-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2007-09-27 | — | — | US | disclosed |
| US-7268153-B2 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-09-11 | — | — | US | disclosed |
| CN-1976902-A | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK & CO INC (US) | 2007-06-06 | — | — | CN | disclosed |
| EP-1755572-A2 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005120477-A2 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277681-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277681-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | SHBG, AR, BRCA1 | ALDH1A1 2768/4885MEN1 3096/4885KMT2A 1189/4885 |
| US-20160102100-A1 | FUSED HETEROCYCLIC COMPOUND | NR4A1, CYP4B1, NR1H4 | ALDH1A1 2549/4885MEN1 1606/4885KMT2A 2282/4885 |
| US-20070225229-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | SHBG, AR, BRCA1 | ALDH1A1 2768/4885MEN1 3096/4885KMT2A 1189/4885 |
| US-20080139630-A1 | N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators | SHBG, AR, NR5A1 | ALDH1A1 2873/4885MEN1 3173/4885KMT2A 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.